ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
How to decrease HIV related belly fat accumulation
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 189814" data-attributes="member: 3"><p>My latest HIV lecture:</p><p></p><p>[MEDIA=youtube]n78vXeoMmI8[/MEDIA]</p><p></p><p>Nelson Vergel, founder of PoWeRUSA.org, covers the following topics:</p><p></p><ol> <li data-xf-list-type="ol">Weight Gain in the New HIV Era- Review of Studies</li> <li data-xf-list-type="ol">Preventing Heart Disease</li> <li data-xf-list-type="ol">Reducing Visceral Fat</li> <li data-xf-list-type="ol">Healthy Nutrition Tips</li> <li data-xf-list-type="ol">Exercise Tips</li> <li data-xf-list-type="ol">Weight Loss Medications</li> <li data-xf-list-type="ol">Hormone Balance</li> <li data-xf-list-type="ol">Sleep- The Pillar of Health</li> <li data-xf-list-type="ol">Resources</li> </ol><p></p><p><strong><u>Weight Gain in HIV: Then and Now:</u></strong></p><p><strong></strong></p><p><strong>1996- 2006:</strong></p><p></p><p>Weight gain was characterized by accumulation in the visceral and cervical area (lipohypertrophy) in the boosted protease plus thymidine nucleoside era (Crixivan, Kaletra, AZT, Zerit) along with fat loss under the skin (lipoatrophy). Lipoatrophy decreased after Zerit and AZT were no longer recommended in the U.S. in 2004. ARV-related mitochondrial toxicity plus insulin resistance were factors identified in body changes along with inflammatory cytokines. Some genetic factors were also identified but not investigated in detail. The term “lipodystrophy”” was later changed to “return-to-health” syndrome as strong immune reconstitution was identified as a major factor.</p><p></p><p><strong>2006-2020:</strong></p><p></p><p>The only treatment approved for the treatment of increased abdominal fat is Egrifta SR.</p><p></p><p>We hoped that integrase inhibitors would not cause weight gain since they are not associated with mitochondrial toxicity or insulin resistance. They were later found to cause greater weight gain than protease inhibitors in naïve patients and those switching to integrase inhibitors. This trend is most pronounced in women, blacks, and persons ≥ 60 yrs. of age.</p><p></p><p>We have learned that all antiretrovirals (ARVs) can cause weight gain and that patient-related factors that may worsen their effect. Fortunately, disfiguring lipodystrophy is rare in patients not exposed to AZT, Zerit and older ARVs. However, many long-term survivors are still dealing with these body changes.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 189814, member: 3"] My latest HIV lecture: [MEDIA=youtube]n78vXeoMmI8[/MEDIA] Nelson Vergel, founder of PoWeRUSA.org, covers the following topics: [LIST=1] [*]Weight Gain in the New HIV Era- Review of Studies [*]Preventing Heart Disease [*]Reducing Visceral Fat [*]Healthy Nutrition Tips [*]Exercise Tips [*]Weight Loss Medications [*]Hormone Balance [*]Sleep- The Pillar of Health [*]Resources [/LIST] [B][U]Weight Gain in HIV: Then and Now:[/U] 1996- 2006:[/B] Weight gain was characterized by accumulation in the visceral and cervical area (lipohypertrophy) in the boosted protease plus thymidine nucleoside era (Crixivan, Kaletra, AZT, Zerit) along with fat loss under the skin (lipoatrophy). Lipoatrophy decreased after Zerit and AZT were no longer recommended in the U.S. in 2004. ARV-related mitochondrial toxicity plus insulin resistance were factors identified in body changes along with inflammatory cytokines. Some genetic factors were also identified but not investigated in detail. The term “lipodystrophy”” was later changed to “return-to-health” syndrome as strong immune reconstitution was identified as a major factor. [B]2006-2020:[/B] The only treatment approved for the treatment of increased abdominal fat is Egrifta SR. We hoped that integrase inhibitors would not cause weight gain since they are not associated with mitochondrial toxicity or insulin resistance. They were later found to cause greater weight gain than protease inhibitors in naïve patients and those switching to integrase inhibitors. This trend is most pronounced in women, blacks, and persons ≥ 60 yrs. of age. We have learned that all antiretrovirals (ARVs) can cause weight gain and that patient-related factors that may worsen their effect. Fortunately, disfiguring lipodystrophy is rare in patients not exposed to AZT, Zerit and older ARVs. However, many long-term survivors are still dealing with these body changes. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
How to decrease HIV related belly fat accumulation
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top